RYBREVANT FASPRO

amivantamab and hyaluronidase-lpuj (human recombinant) · Janssen Biotech, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RYBREVANT FASPRO, covering 2025-12-17 to 2026-02-13. Get the full timeline:

Most recent: FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)